Exposure to Therapeutic BTK Inhibitors Induces Phenocopying of


Journal

Frontiers in bioscience (Landmark edition)
ISSN: 2768-6698
Titre abrégé: Front Biosci (Landmark Ed)
Pays: Singapore
ID NLM: 101612996

Informations de publication

Date de publication:
27 06 2023
Historique:
received: 19 04 2023
revised: 22 05 2023
accepted: 01 06 2023
medline: 4 7 2023
pubmed: 3 7 2023
entrez: 3 7 2023
Statut: ppublish

Résumé

Bruton's tyrosine kinase (BTK) is a non-receptor type tyrosine kinase originally identified as the genetic signature responsible for X-linked agammaglobulinemia (XLA) when mutated. Its functional form is required for B lymphocyte maturation in both humans and mice, whereas loss-of-function causes a different form of developmental defect in the fruit fly, Ibrutinib and other therapeutic inhibitors of BTK have been extensively used to successfully treat various leukemias and lymphomas. We have previously reported that Thus,

Sections du résumé

BACKGROUND
Bruton's tyrosine kinase (BTK) is a non-receptor type tyrosine kinase originally identified as the genetic signature responsible for X-linked agammaglobulinemia (XLA) when mutated. Its functional form is required for B lymphocyte maturation in both humans and mice, whereas loss-of-function causes a different form of developmental defect in the fruit fly,
METHODS
Ibrutinib and other therapeutic inhibitors of BTK have been extensively used to successfully treat various leukemias and lymphomas.
RESULTS
We have previously reported that
CONCLUSIONS
Thus,

Identifiants

pubmed: 37395037
pii: S2768-6701(23)00913-9
doi: 10.31083/j.fbl2806124
doi:

Substances chimiques

Protein-Tyrosine Kinases EC 2.7.10.1
beta Catenin 0
Agammaglobulinaemia Tyrosine Kinase EC 2.7.10.2

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

124

Informations de copyright

© 2023 The Author(s). Published by IMR Press.

Déclaration de conflit d'intérêts

The authors declare no conflict of interest.

Auteurs

Noriko Hamada-Kawaguchi (N)

Department of Laboratory Medicine, Translational Research Center Karolinska (TRACK), Karolinska Institutet, Karolinska University Hospital, SE-141 86 Stockholm, Sweden.
Department of Molecular Biosciences, The Wenner-Gren Institute, Stockholm University, SE-106 91 Stockholm, Sweden.

Beston F Nore (BF)

Food Science Technology, School of Applied Sciences and Mathematics (SASM), University Technology Brunei (UTB), BE1410 Mukim Gadong A, Brunei Darussalam.

Rula Zain (R)

Department of Laboratory Medicine, Translational Research Center Karolinska (TRACK), Karolinska Institutet, Karolinska University Hospital, SE-141 86 Stockholm, Sweden.
Center for Rare Diseases, Karolinska University Hospital, SE-171 76 Stockholm, Sweden.

Ylva Engström (Y)

Department of Molecular Biosciences, The Wenner-Gren Institute, Stockholm University, SE-106 91 Stockholm, Sweden.

C I Edvard Smith (CIE)

Department of Laboratory Medicine, Translational Research Center Karolinska (TRACK), Karolinska Institutet, Karolinska University Hospital, SE-141 86 Stockholm, Sweden.

Daisuke Yamamoto (D)

Neuro-ICT Laboratory, Advanced Institute of Information and Communications Technology, 651-2492 Kobe, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH